还原型谷胱甘肽治疗尿毒症贫血的初步探讨

目的　观察外源性还原型谷胱甘肽对尿毒症贫血的治疗效果。方法　将 42例尿毒症贫血患者随机分为两组。两组患者均给予重组人红细胞生成素 (r- Hu EPO) 30 0 0 U,每周两次皮下注射 ,疗程 12周。治疗组患者同时静脉给予外源性还原型谷胱甘肽 (GSH) 12 0 0 mg,每周两次 ,疗程 12周。于治疗前和治疗后抽静脉血测定血红蛋白 (Hb) ,红细胞 (RBC)和红细胞压积 (HCT)水平。结果　 r- Hu EPO治疗后两组患者 HB,RBC和 HCT水平均显著上升 (P<0 .0 1)。 GSH治疗组 Hb,RBC和 HCT水平与对照组比较上升明显 (P<0 .0 5 ) ,治疗组 Hb,RBC和HCT的上升幅度高于对照组 (P<0 .0 5 )。结论　外源性还原型谷胱甘肽能显著提高 r- Hu EPO治疗肾性贫血的疗效 ,GSH可能是治疗尿毒症贫血的有效药物。

A Therapeutical Approach by Administering Reduced Glutathione to Patients with Uremic Anemia

Objective To verify the therapeutical effect of exogenous reduced glutathione(GSH) on the patients with uremic anemia. Methods Forty two patients with uremic anemia were randomly divided into treatment group and control group. All patients received subcutaneously recombinant human erythropoietin (r HuEPO) at the dose of 3000U twice a week for 12 weeks. Each of the patients in the treatment group was given intravenously reduced glutathione at the dose of 1200mg twice a week for 12 weeks. The measurements of hemoglobin, red blood cells and hematocrit were performed. Results After administration of r HuEPO, the levels of hemoglobin, red blood cells and hematocrit were significantly elevated in both treatment and control groups ( P <0.01). The levels of hemoglobin, red blood cells and hematocrit in treatment group were elevated much more obviously, compared with those in control group ( P <0.05). Conclusion These findings seem to indicate that exogenous GSH could enhance the effect of r HuEPO on uremic anemia,and therefore it might represent a useful drug in the treatment and management of uremic anemia.